Cardiac metabolism — A promising therapeutic target for heart failure-Reference-Cited by-同舟云学术

Cardiac metabolism — A promising therapeutic target for heart failure

Published:2018-02 Issue: Volume:182 Page:95-114
ISSN:0163-7258
Container-title:Pharmacology & Therapeutics
language:en
Short-container-title:Pharmacology & Therapeutics

Author:

Noordali Hannah,Loudon Brodie L.,Frenneaux Michael P.,Madhani Melanie

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference298 articles.

1. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy;Abozguia;Circulation,2010

2. Reduced SIRT1 expression correlates with enhanced oxidative stress in compensated and decompensated heart failure;Akkafa;Redox Biology,2015

3. Compensated cardiac hypertrophy is characterised by a decline in palmitate oxidation;Akki;Molecular and Cellular Biochemistry,2008

4. Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-gamma coactivator 1alpha;Arany;Proceedings of the National Academy of Sciences of the United States of America,2006

5. Proceedings: A comparative study of perhexiline, beta-adrenergic blocking agents and placebos in the management of angina pectoris;Armstrong;Postgraduate Medical Journal,1973

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insights into the post-translational modifications in heart failure;Ageing Research Reviews;2024-09

2. Fluorinated perhexiline derivative attenuates vascular proliferation in pulmonary arterial hypertension smooth muscle cells;Vascular Pharmacology;2024-09

3. Comparative proteomics reveals that fatty acid metabolism is involved in myocardial adaptation to chronic hypoxic injury;PLOS ONE;2024-06-17

4. The JMJD family of histone demethylase and their intimate links to cardiovascular disease;Cellular Signalling;2024-04

5. Integrated analysis reveals the dysfunction of intercellular communication and metabolic signals in dilated cardiomyopathy;Heliyon;2024-03